Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration

International Journal of Pharmaceutics

Volumn 452, Issue 1-2, 2013, Pages 344-354

  Yang, Zhen Zhen ^a   Zhang, Yan Qing ^b   Wang, Zhan Zhang ^a   Wu, Kai ^a   Lou, Jin Ning ^c   Qi, Xian Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN UNIVERSITY OF COMMERCE   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Biodistribution; Cell penetrating peptide (CPP); Intranasal administration; Liposomes; Pharmacodynamics; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; CELL PENETRATING PEPTIDE; CHOLINESTERASE; LIPOSOME; RIVASTIGMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CEREBELLUM; CILIARY MOTILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG RETENTION; DRUG TRANSPORT; DRUG URINE LEVEL; ELECTRIC RESISTANCE; HEMOLYSIS; HIPPOCAMPUS; IN VITRO STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; SHEEP ERYTHROCYTE; SPLEEN;

EID: 84884206111     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.009     Document Type: Article

References (42)

1. Ballard, C.G., 2002. Advances in the treatment of Alzheimer's disease: benefits ofdual cholinesterase inhibition. Eur. Neurol. 47, 64-70.
2. Bar-On, P., Millard, C.B., Harel, M., Dvir, H., Enz, A., Sussman, J.L., Silman, I., 2002. Kinetic and structural studies on the interaction of cholinesterases with theanti-Alzheimer drug rivastigmine. Biochemistry 41, 3555-3564. (Pubitemid 34224667)
3. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of micro-gram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
4. Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buee-Scherrer, V.V., Duhem, C.,Lundquist, S., Rentfel, M., Torpier, G., Dehouck, M.P., 1999. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev.36, 165-178. (Pubitemid 29121970)
5. Dahl, R., Mygind, N., 1998. Anatomy, physiology and function of the nasal cavities in health and disease. Adv. Drug Deliv. Rev. 29, 3-12. (Pubitemid 28044084)
6. Du, L., Kayali, R., Bertoni, C., Fike, F., Hu, H., Iversen, P.L., Gatti, R.A., 2011. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum. Mol. Genet. 20, 3151-3160.
7. Fritze, A., Hens, F., Kimpfler, A., Schubert, R., Peschka-Suss, R., 2006. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta 1758, 1633-1640. (Pubitemid 44466698)
8. Haran, G., Cohen, R., Bar, L.K., Barenholz, Y., 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151, 201-215. (Pubitemid 23283973)
9. Hirai, S., Yashika, S., Matsuzawa, T., Mima, H., 1981. Absorption of drugs from thenasal mucosa of rat. Int. J. Pharm. 7, 317-325. (Pubitemid 11158883)
10. Illum, L., 2000. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11, 1-18. (Pubitemid 30410839)
11. Illum, L., 2003. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 87, 187-98. (Pubitemid 36255456)
12. Jann, M.W., 2000. Rivastigmine, a new-generation cholinesterase inhibitor for thetreatment of Alzheimer's disease. Pharmacotherapy 20, 1-12. (Pubitemid 30036098)
13. Jogani, V.V., Shah, P.J., Mishra, P., Mishra, A.K., Misra, A.R., 2008. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord. 22, 116-124.
14. Kabanov, A.V., Batrakova, E.V., Alakhov, V.Y., 2002. Pluronic block copolymers asnovel polymer therapeutics for drug and gene delivery. J. Control. Release 82,189-212. (Pubitemid 34880178)
15. Kaur, P., Kim, K., 2008. Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. Int. J. Pharm. 364, 27-35.
16. Khafagy el, S., Morishita, M., Isowa, K., Imai, J., Takayama, K., 2009. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 133,103-108.
17. Leonard, A.K., Sileno, A.P., MacEvilly, C., Foerder, C.A., Quay, S.C., Costantino, H.R., 2005. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J. Pharm. Sci. 94, 1736-746. (Pubitemid 41360868)
18. Ma, D.X., Shi, N.Q., Qi, X.R., 2011. Distinct transduction modes of arginine-richcell-penetrating peptides for cargo delivery into tumor cells. Int. J. Pharm. 419, 200-208.
19. Mistry, A., Stolnik, S., Illum, L., 2009. Nanoparticles for direct nose-to-brain deliveryof drugs. Int. J. Pharm. 379, 146-157.
20. Mutlu, N.B., Degim, Z., 2005. Bioavailability file: rivastigmine tartrate. J. Pharm. Sci.30, 150-157.
21. Na, L., Mao, S., Wang, J., Sun, W., 2010. Comparison of different absorption enhancerson the intranasal absorption of isosorbide dinitrate in rats. Int. J. Pharm. 397, 59-66.
22. Nonaka, N., Farr, S.A., Kageyama, H., Shioda, S., Banks, W.A., 2008. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J. Pharmacol. Exp. Ther. 325, 513-519. (Pubitemid 351574811)
23. Pakaski, M., Kalman, J., 2008. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem. Int. 53, 103-111.
24. Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Huls, C., Zetterberg, H.,Minthon, L., Wallin, A.K., Andreasen, N., Talesa, V.N., Blennow, K., 2011. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurol. Scand. 124,122-129.
25. Polinsky, R.J., 1998. Clinical pharmacology of rivastigmine: a new-generation acetyl-cholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 20, 634-647. (Pubitemid 28421485)
26. Puchelle, E., Zahm, J.M., Sadoul, P., 1982. Mucociliary frequency of frog palate epithelium. Am. J. Physiol. 242, C31-C35. (Pubitemid 12098495)
27. Saw, P.E., Ko, Y.T., Jon, S., 2010. Efficient liposomal nanocarrier-mediated oligodeoxynucleotide delivery involving dual use of a cell-penetrating peptide as a packaging and intracellular delivery agent. Macromol. Rapid Commun. 31, 1155-1162.
28. Scali, C., Casamenti, F., Bellucci, A., Costagli, C., Schmidt, B., Pepeu, G., 2002. Effect of subchronic administration of metrifonate, rivastigmine anddonepezil on brain acetylcholine in aged F344 rats. J. Neural Transm. 109, 1067-1080. (Pubitemid 34762345)
29. Schnyder, A., Huwyler, J., 2005. Drug transport to brain with targeted liposomes. NeuroRx 2, 99-107. (Pubitemid 40128030)
30. Spencer, C.M., Noble, S., 1998. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 13, 391-411. (Pubitemid 28523796)
31. Tenovuo, O., 2005. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury - clinical experience in 111 patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 61-67. (Pubitemid 40018206)
32. Torchilin, V.P., 2008. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60, 548-558. (Pubitemid 351215572)
33. Trabulo, S., Cardoso, A.L., Mano, M., MCP, D.L., 2010. Cell-penetratingpeptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 3, 961-993.
34. van Bree, J.B., de Boer, A.G., Danhof, M., Ginsel, L.A., Breimer, D.D., 1988. Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J. Pharmacol. Exp. Ther. 247, 1233-1239. (Pubitemid 19022140)
35. Venkatesh, K., Bullock, R., Akbas, A., 2007. Strategies to improve tolerability of rivastigmine: a case series. Curr. Med. Res. Opin. 23, 93-95. (Pubitemid 46191674)
36. Westin, U.E., Bostrom, E., Grasjo, J., Hammarlund-Udenaes, M., Bjork, E., 2006. Directnose-to-brain transfer of morphine after nasal administration to rats. Pharm. Res. 23, 565-572.
37. Williams, B.R., Nazarians, A., Gill, M.A., 2003. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin. Ther. 25, 1634-1653. (Pubitemid 36801939)
38. Xie, Y., Ye, L.Y., Zhang, X.B., Hou, X.P., Lou, J.N., 2004. Establishment of an in vitro>model of brain-blood barrier. Beijing Da Xue Xue Bao 36, 435-438.
39. Xie, Y., Ye, L.Y., Zhang, X., Cui, W., Lou, J., Nagai, T., Hou, X., 2005. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier:in vitro and in vivo studies. J. Control. Release 105, 106-119. (Pubitemid 40805479)
40. Yang, Z.Z., Zhang, Y.Q., Wu, K., Wang, Z.Z., Qi, X.R., 2012. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administrationin rats. Curr. Alzheimer Res. 9, 315-325.
41. Zhang, Q., Jiang, X., Jiang, W., Lu, W., Su, L., Shi, Z., 2004. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 275, 85-96. (Pubitemid 38481522)
42. Zhang, X., Jin, Y., Plummer, M.R., Pooyan, S., Gunaseelan, S., Sinko, P.J., 2009. Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9,a retro-inverso Tat cell penetrating peptide. Mol. Pharmacol. 6, 836-848.